MIRM Stock Overview A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Mirum Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Mirum Pharmaceuticals Historical stock prices Current Share Price US$42.17 52 Week High US$48.89 52 Week Low US$23.14 Beta 0.96 1 Month Change -6.60% 3 Month Change 8.55% 1 Year Change 40.75% 3 Year Change 168.43% 5 Year Change 77.26% Change since IPO 219.23%
Recent News & Updates See more updates
Mirum Pharma: Buy At Dips For Volixibat Potential Dec 25
Investors Aren't Buying Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Revenues Dec 09
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results Nov 15
Mirum Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt? Nov 03
Mirum Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Volixibat in Treating Cholestatic Pruritus in PBC Oct 11
Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish Oct 04
Mirum Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
Mirum Pharmaceuticals, Inc’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Olderer Jul 26
Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition Jul 17
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth Jul 13
Mirum Pharmaceuticals, Inc.' LIVMARLI Approves in the European Union for Patients with PFIC Jul 08
Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older Jun 01
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry May 28
Forecast breakeven date pushed back to 2026 May 28
Mirum Pharmaceuticals, Inc Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC May 09
Mirum Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Mirum Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024 Apr 24
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value Apr 22
Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada’S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome Apr 03
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis Mar 14
Mirum Pharmaceuticals: Advancing On Several Key Fronts Mar 05
Mirum Pharmaceuticals, Inc. announced delayed annual 10-K filing Mar 01 Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024
Mirum Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 22
CEO & Director recently sold US$157k worth of stock Feb 09
Mirum Pharmaceuticals, Inc. Announces Management Changes Jan 17
Mirum Pharmaceuticals, Inc. Announces Management Appointments Jan 16
Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023 Jan 09
There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price Dec 26
Price target decreased by 12% to US$48.30 Dec 19
Mirum Pharmaceuticals, Inc. Announces Data from EMBARK Phase 2b Study for Biliary Atresia Dec 18
Mirum Pharmaceuticals, Inc. Presents New Data at the Liver Meeting Nov 14
Forecast breakeven date pushed back to 2025 Nov 07
Price target decreased by 7.2% to US$53.57 Nov 07
Mirum Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Nov 04
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 03 Mirum Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Nov 03
Consensus estimates of losses per share improve by 22% Oct 19
Mirum Pharmaceuticals, Inc. Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis Oct 18
Mirum Pharmaceuticals, Inc. Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN Oct 10
Mirum Pharmaceuticals, Inc. Announces Positive Phase 3 Restore Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis Oct 05
Price target increased by 7.1% to US$59.20 Sep 20
Insider recently bought US$296k worth of stock Sep 13
Mirum Pharmaceuticals, Inc. Appoints Eric Bjerkholt as the Chief Financial Officer Sep 12
Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX). Sep 06
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 04
Mirum Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Mirum Pharmaceuticals's LIVMARLI Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome Jul 26
Forecast breakeven date moved forward to 2024 Jul 18 Mirum Pharmaceuticals, Inc. announced that it expects to receive $210 million in funding from Frazier Life Sciences Management, LP, Avidity Partners Management, L.P., BVF Partners L.P., Longitude Capital Management Co., LLC, Sofinnova Investment, Inc. and another investor Jul 18
President recently sold US$141k worth of stock Jul 10
Mirum Pharmaceuticals, Inc. Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress Jun 24
New major risk - Financial position Jun 15
What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You Jun 10
Mirum Pharmaceuticals, Inc. Announces Data from It's LIVMARLI Studies Presented at ESPGHAN Annual Meeting May 20
Mirum Pharmaceuticals, Inc. Announces Hepatology Communications Publishes Data from CAMEO Study Evaluating Safety, Tolerability, and Efficacy of LIVMARLI® (Maralixibat) Oral Solution in Patients with Primary Sclerosing Cholangitis May 19
Mirum Pharmaceuticals, Inc. Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study May 12
No longer forecast to breakeven May 08
Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts Apr 18
Consensus revenue estimates increase by 16% Apr 13
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis Feb 15
Mirum Pharmaceuticals, Inc. Announces Resignation of Ian Clements as Chief Financial Officer Jan 10
Forecast to breakeven in 2025 Dec 31
Mirum Pharmaceuticals, Inc. Announces Resignation of Carol L. Brosgart, M.D. as A Director of the Company and as A Member of the Nominating and Corporate Governance Committee of the Board, Effective December 19, 2022 Dec 21
Mirum Pharmaceuticals, Inc. Appoints Lon Cardon to Board of Directors Dec 20
Mirum Pharmaceuticals, Inc. Announces LIVMARLI (maralixibat) Approval by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older Dec 13 Mirum Pharmaceuticals Provides Development Program Updates
Forecast to breakeven in 2024 Nov 26
Mirum Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Nov 02
Mirum Pharmaceuticals, Inc. Reports Positive Topline Data from Its Phase 3 March Study Oct 27
Price target increased to US$56.63 Oct 26
Mirum Pharmaceuticals, Inc. Announces Positive Topline Results from Its Pivotal Phase 3 March Study Evaluating Livmarli Oct 25
Mirum Pharmaceuticals’ announces LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics Oct 19
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older Oct 15
Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU Oct 14
Price target decreased to US$51.43 Oct 12
No longer forecast to breakeven Sep 09
Mirum Pharmaceuticals, Inc. Announces Resignation of Edward T. Mathers as A Member of the Compensation Committee of the Board, Effective September 1, 2022 Sep 03
Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth Aug 17
Mirum Pharmaceuticals announces $80M stock offering Aug 09
Mirum Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Mirum Pharmaceuticals, Inc.(NasdaqGM:MIRM) dropped from Russell Microcap Value Index Jun 26
Mirum Pharmaceuticals Highlights Data Demonstrating Impact of Livmarli® (Maralixibat) on Patients with Alagille Syndrome Jun 25
Mirum Pharmaceuticals, Inc. Appoints Saira Ramasastry to the Board of Directors and as A Member of the Audit Committee Jun 07
Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent May 27
Forecast to breakeven in 2024 May 24
Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) acquired Satiogen Pharmaceuticals, Inc. for approximately $21.5 million. May 24
Forecast to breakeven in 2024 May 21 Shareholder Returns MIRM US Biotechs US Market 7D 2.5% -3.3% -0.4% 1Y 40.8% -2.7% 24.8%
See full shareholder returns
Return vs Market: MIRM exceeded the US Market which returned 24.8% over the past year.
Price Volatility Is MIRM's price volatile compared to industry and market? MIRM volatility MIRM Average Weekly Movement 5.3% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: MIRM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MIRM's weekly volatility (5%) has been stable over the past year.
About the Company Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
Show more Mirum Pharmaceuticals, Inc. Fundamentals Summary How do Mirum Pharmaceuticals's earnings and revenue compare to its market cap? MIRM fundamental statistics Market cap US$2.02b Earnings (TTM ) -US$99.81m Revenue (TTM ) US$307.03m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MIRM income statement (TTM ) Revenue US$307.03m Cost of Revenue US$83.88m Gross Profit US$223.15m Other Expenses US$322.96m Earnings -US$99.81m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.08 Gross Margin 72.68% Net Profit Margin -32.51% Debt/Equity Ratio 132.6%
How did MIRM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 01:05 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Mirum Pharmaceuticals, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Joshua Schimmer Cantor Fitzgerald & Co. David Lebowitz Citigroup Inc
Show 11 more analysts 
